RNA polymerase and Kinase

The entry 'RNA polymerases, kinases' refers to two distinct and major superfamilies of enzymes that are central to cellular biology and therapeutic intervention. RNA polymerases are responsible for transcribing genetic information from DNA or RNA templates into various forms of RNA, a process essential for protein synthesis and viral replication [6, 10]. Kinases are phosphotransferases that catalyze the transfer of phosphate groups to specific substrates, acting as primary regulators of signal transduction, metabolism, and the cell cycle [9, 12]. These two classes are functionally interconnected; for instance, specific cyclin-dependent kinases (e.g., CDK7 and CDK9) regulate the activity of RNA polymerase II by phosphorylating its C-terminal domain to control the transition from transcription initiation to elongation [5, 10]. From a pharmacological perspective, these enzymes are among the most important targets in modern medicine. RNA polymerases are critical targets for antibacterial drugs like Rifampicin and antivirals like Remdesivir and Sofosbuvir [6, 8, 13]. Kinases are primary targets in oncology (e.g., Imatinib for leukemia) and immunology (e.g., JAK inhibitors for rheumatoid arthritis) [1, 5, 9]. However, because this grouping encompasses thousands of different proteins with diverse structures and functions, it does not represent a single, well-defined therapeutic target but rather two broad categories of enzymes often identified in large-scale drug screening or genomic studies [2, 4, 14].

Other names

RNA polymeraseProtein kinasePhosphotransferaseTranscriptional kinaseNucleoside kinaseRdRp (RNA-dependent RNA polymerase)RNAP

Inhibition of RNA synthesis by binding to the polymerase active site or allosteric pockets; inhibition of phosphorylation-mediated signaling by competing with ATP for the kinase binding site.